Fluidigm Corporation (FLDM)
(Delayed Data from NSDQ)
$11.89 USD
-1.80 (-13.15%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.89 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.89 USD
-1.80 (-13.15%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.89 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Fluidigm (FLDM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fluidigm (FLDM) delivered earnings and revenue surprises of -225.00% and -11.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Fluidigm (FLDM) Q4 Earnings Expected to Decline
by Zacks Equity Research
Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Looking for a Growth Stock? Why It is Time to Focus on Fluidigm (FLDM)
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Fluidigm (FLDM).
Fluidigm (FLDM) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Fluidigm (FLDM) delivered earnings and revenue surprises of 150.00% and 19.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Fluidigm (FLDM) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD's (BDX) COVID-19 Real-Time PCR Detection Kit Gets CE Mark
by Zacks Equity Research
BD's (BDX) Real Time PCR Detection Kit enables BD MAX System users to run a single module that tests concurrently for COVID-19, flu and RSV.
Coronavirus Test Makers With Scope to Maximize Investor Benefits
by Urmimala Biswas
The surge in new coronavirus infections broadens the scope for antigen and antibody tests.
Fluidigm (FLDM) Looks Good: Stock Adds 8.7% in Session
by Zacks Equity Research
Fluidigm (FLDM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Implied Volatility Surging for Fluidigm (FLDM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Fluidigm (FLDM) stock based on the movements in the options market lately.
Analysts Estimate Fluidigm (FLDM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Fluidigm (FLDM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (FLDM) Outperforming Other Medical Stocks This Year?
Snap Up These 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top--ranked stocks with rising P/E to realize outsized gains.
Earnings Preview: Fluidigm (FLDM) Q4 Earnings Expected to Decline
by Zacks Equity Research
Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fluidigm (FLDM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fluidigm (FLDM) delivered earnings and revenue surprises of 0.00% and -8.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Fluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fluidigm (FLDM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fluidigm (FLDM) delivered earnings and revenue surprises of -40.00% and 4.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Masimo Gets CE Mark for ANI Module, Enhances Root Platform
by Zacks Equity Research
Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.
Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings?
by Zacks Equity Research
Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.
Fluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in DENTSPLY (XRAY) Stock Now
by Zacks Equity Research
Strong prospects in emerging markets provide DENTSPLY (XRAY) a competitive edge in the MedTech space.
AngioDynamics' (ANGO) Q3 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Despite strength in the VIT business, AngioDynamics (ANGO) exited third-quarter fiscal 2019 on a tepid note, with both earnings and revenues missing estimates.
Glaukos (GKOS) Banks on Solid Pipeline Amid Stiff Competition
by Zacks Equity Research
Glaukos' (GKOS) strong pipeline is indicative of brighter prospects ahead. However, cutthroat competition in the medical-device industry is worrisome.
AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study
by Zacks Equity Research
AngioDynamics' (ANGO) launches AngioDIRECT.com for enrolling participants as part of the DIRECT clinical study.
Fluidigm (FLDM) in Focus: Stock Moves 8% Higher
by Zacks Equity Research
Fluidigm (FLDM) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.